Good Clinical Practice Journal

Below are the titles of articles published in the Good Clinical Practice Journal Volume 6 Issue 5 (September/October 1999).

Copies of back issues and individual articles are available direct from the publisher � please contact us for further information.

"The Use of Computer Assisted Design to Support Good Clinical Trials"
by Dr E Snoeck

Abstract
Computer simulation of clinical trials allows us to minimise the risk of trial failure. Multiple "what if" scenarios can be tested before embarking on the clinical trial process itself. This will allow researchers to optimize the design of clinical trials, increasing the predictability of the process and the likelihood that each trial will yield definitive results.


"Motivating patients to participate in clinical trials"
by Keith Lilley

Abstract
At the present time, there is a notable shift of emphasis within clinical research circles towards the importance of strategies to optimise patient recruitment, compliance and retention. No longer is it accepted as the norm that clinical studies will inevitably slip and stall in relation to their original timeline forecasts. The challenge, within what seems to be an increasingly difficult research environment, of meeting and beating recruitment targets - or indeed of recruiting any patients at all - is discussed.


"Out-sourcing to Independent Consultants"
by Francois Geelen

Abstract
Outsourcing is increasing in almost every industry. Experienced personnel are continually seeking the rewards and flexibility offered by 'going freelance'. The author comments, from his experience, on the benefits and failings of using freelance help to complete a clinical study.


"Size matters"
Fiona Jones interviews Philip Ledger

Abstract
Recent merger activity within the pharmaceutical industry would suggest that 'big is best'. But is this the reality? Fiona Jones interviews Philip Ledger, a consultant to small biopharmaceutical companies and learns that these companies are playing an ever increasing role in drug development. The motivation of small companies is different, they require passionate leadership and an extensive support network. Their key advantage is their willingness to be innovative, to make changes and to respond rapidly to market need. Perhaps as we enter the new millennium we will learn that often the best things really do come in small packages.